Zscaler, Inc.

Executive Summary

HOLD, High conviction. Rated HOLD, High conviction. Zscaler is executing well, Q4 revenue and ARR both grew 25%, and FY27 free cash flow margin guidance of 23% to 23.5% shows durable earnings power. But the stock at $193.05 already sits 15.3% above its 200-day average, while the quant price target is $189.11, and FY27 guidance marks a clear growth deceleration to 16.6% to 17.5%.

Investment Thesis

Zscaler remains a good company, but the stock is no longer obviously cheap enough to underwrite a strong upside call. The core business is healthy. Q4 revenue reached $898M, up 25%, ARR hit $3.8B, up 25%, and non-GAAP operating margin reached a record 24.3%. Those are strong numbers. The issue is the direction from here. FY27 guidance calls for $3.908B to $3.938B of revenue and $4.396B to $4.426B of ARR, both only 16.6% to 17.5% growth. That is still solid, but it is a meaningful step down from the recent reported pace.

The bullish case depends on three things. First, AI demand has to convert from strong interest into durable growth. So far the signs are real: security for AI bookings grew more than 50% sequentially, and metered usage products made up ~30% of new and upsell ACV, with related ARR growing over 100% y/y. Second, margin expansion has to stick. Q1 guidance implies 23% operating margin, and FY27 free cash flow margin is guided to 23% to 23.5%, so this is not a pure growth-at-any-cost story. Third, the platform must keep broadening inside large enterprises, and the rise in Zero Trust Everywhere customers to more than 950 from over 700 in Q3 supports that.

The bearish case is simpler: the stock price already reflects much of that quality. At 10.26x sales, ZS trades roughly in line with the 10.6x peer average, not at a clear discount. The quant framework lands at $189.11, below the current $193.05, and the valuation cross-check is messy because DCF is far below the multiple-based methods. That usually means future growth and margins need to stay strong just to hold the stock where it is. The latest CRO departure adds one more variable at a moment when management already said the sales leadership transition would affect 1H FY27.

The right stance is disciplined patience. ZS is not broken. It is executing. But after a 31.03% move in the last three months and with the shares now 15.3% above the 200-day average, the setup looks more balanced than asymmetric. A better entry would require either a cheaper price or proof that FY27's ~17% guide is too conservative.

Key Metrics

Financial Strength

The financial profile is better than the GAAP P&L suggests, but not clean enough to wave away valuation discipline. The business is showing real operating leverage, with record 24.3% non-GAAP operating margin in Q4 and FY27 free cash flow margin guided at 23% to 23.5%. That said, FY2026 still showed -4.2% operating margin, -$0.39 EPS, and only $0.1B of free cash flow, while leverage screens elevated at 9.95x Debt/EBITDA with $1.9B of debt. Elevated FY27 CapEx in the low teens percent of revenue also matters because it tempers near-term cash conversion even as the model scales.

Competitive Position

Zscaler's moat rests on large-scale cloud-native traffic inspection, Zero Trust architecture, and an expanding platform that is moving beyond seat-based products into usage-based security services. The evidence that this moat is broadening is concrete: non-seat-based products represented ~30% of new and upsell ACV, related ARR grew over 100% y/y, and Zero Trust Everywhere customers rose to more than 950 from over 700 in one quarter. That said, durability over the next 3 to 5 years depends on whether Zscaler can turn AI-related demand into standard platform spend before rivals bundle similar capabilities into larger security suites.

Management & Guidance

Management is guiding conservatively but credibly. CFO Kevin Rubin said, "For the full year fiscal '27, we expect ARR of $4.396 billion to $4.426 billion or year-over-year growth of approximately 16.6% to 17.4%. Revenue of $3.908 billion to $3.938 billion, reflecting year-over-year growth of 16.6% to 17.5%." That slowdown deserves respect, especially with Red Canary contributing no net new ARR in FY27 and the sales leadership transition playing out in 1H FY27. At the same time, credibility is high because ZS has delivered 8 straight EPS beats, including 1.19 vs 1.09 in the latest quarter, and management paired the slower growth guide with healthy margin and cash flow guidance rather than overpromising on acceleration.

Bull Case

• Demand remains strong in the core platform, with Q4 revenue at $898M, +25% y/y and ARR at $3.8B, +25% y/y, both above guidance.
• AI is helping, not hurting, near-term demand: security for AI bookings increased more than 50% sequentially, and metered usage products contributed ~30% of new and upsell ACV with related ARR up over 100% y/y.
• Margin expansion is tangible, not theoretical: Q4 EBITDA margin reached 11.1%, up 840 bps versus Q3 and 630 bps versus prior-year Q4, while FY27 free cash flow margin is guided to 23% to 23.5%.
• Execution credibility is high on quarterly delivery, with 8 straight EPS beats, ranging from +6.9% to +22.2% versus consensus.

Bear Case

• FY27 guidance is the issue: revenue growth slows to 16.6% to 17.5% from FY26 revenue growth of 19.3% and well below Q4's 25% pace.
• The latest negative setup is company-specific, not macro: the CRO transition is happening as sales leadership changes are expected to play out in 1H FY27, and management explicitly baked that into guidance.
• Profitability is still awkward on GAAP numbers, with FY2026 EPS at -$0.39, net margin -0.6%, and operating margin -4.2%, which limits how far investors should stretch on premium multiples in a 5.11% 10-year Treasury backdrop.
• Balance sheet and cash conversion are decent but not pristine for a software premium name, with Debt/EBITDA 9.95, total debt $1.9B, and FY2026 FCF only $0.1B despite a $34.7B market cap.

Valuation & Price Target

Engine price target $189.11 (-2% vs current), High confidence.

• P/S Multiple: $197.65 (45% weight)
• Quality-adjusted: $202.32 (20% weight)
• DCF: $85.79 (6% weight)

This aligns with the quant baseline HOLD. The firm target is $189.11, or -2.0% from $193.05, and the valuation blend is pulled down by a much lower DCF value of $85.79 even though the multiple-based methods are around $198 to $202. That split makes sense: the business quality is decent at 56/100, execution is strong, but FY27 guidance clearly steps down to ~17% growth and peer comparables are noisy with a 41.5x average P/E and 4.9x dispersion. Sell-side consensus remains Strong Buy (24 buy / 4 hold / 0 sell), but that is low-signal context here and does not outweigh the combination of fair valuation, slower forward growth, and a fresh sales leadership transition.

Risk Assessment

Risk score 43/100 (Moderate). The biggest risk to upside is that FY27 growth settles near management's 16.6% to 17.5% guide while the stock still trades at 10.26x sales, leaving little room for multiple expansion.

The Bottom Line

ZS rates HOLD at High conviction. The business is executing, AI demand looks real, and margins are improving, but the stock already reflects much of that progress at 10.26x sales with guided growth slowing to ~17%. The current setup is not bad, it is just not mispriced enough to chase. A move to BUY would require either a more attractive entry below the current price or proof over the next two quarters that ARR growth can reaccelerate despite the CRO transition. A move to SELL would require evidence that the FY27 guide is still too high or that margin gains are being bought with unsustainably elevated spending.